Cargando…
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patie...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675726/ https://www.ncbi.nlm.nih.gov/pubmed/31173472 http://dx.doi.org/10.1002/cam4.2107 |
| _version_ | 1783440654683078656 |
|---|---|
| author | Mora, Barbara Rumi, Elisa Guglielmelli, Paola Barraco, Daniela Maffioli, Margherita Rambaldi, Alessandro Caramella, Marianna Komrokji, Rami Gotlib, Jason Kiladjian, Jean Jacques Cervantes, Francisco Devos, Timothy Palandri, Francesca De Stefano, Valerio Ruggeri, Marco Silver, Richard T. Benevolo, Giulia Albano, Francesco Cavalloni, Chiara Pietra, Daniela Barbui, Tiziano Rotunno, Giada Cazzola, Mario Vannucchi, Alessandro Maria Giorgino, Toni Passamonti, Francesco |
| author_facet | Mora, Barbara Rumi, Elisa Guglielmelli, Paola Barraco, Daniela Maffioli, Margherita Rambaldi, Alessandro Caramella, Marianna Komrokji, Rami Gotlib, Jason Kiladjian, Jean Jacques Cervantes, Francisco Devos, Timothy Palandri, Francesca De Stefano, Valerio Ruggeri, Marco Silver, Richard T. Benevolo, Giulia Albano, Francesco Cavalloni, Chiara Pietra, Daniela Barbui, Tiziano Rotunno, Giada Cazzola, Mario Vannucchi, Alessandro Maria Giorgino, Toni Passamonti, Francesco |
| author_sort | Mora, Barbara |
| collection | PubMed |
| description | Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM. |
| format | Online Article Text |
| id | pubmed-6675726 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-66757262019-08-06 Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients Mora, Barbara Rumi, Elisa Guglielmelli, Paola Barraco, Daniela Maffioli, Margherita Rambaldi, Alessandro Caramella, Marianna Komrokji, Rami Gotlib, Jason Kiladjian, Jean Jacques Cervantes, Francisco Devos, Timothy Palandri, Francesca De Stefano, Valerio Ruggeri, Marco Silver, Richard T. Benevolo, Giulia Albano, Francesco Cavalloni, Chiara Pietra, Daniela Barbui, Tiziano Rotunno, Giada Cazzola, Mario Vannucchi, Alessandro Maria Giorgino, Toni Passamonti, Francesco Cancer Med Clinical Cancer Research Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM. John Wiley and Sons Inc. 2019-06-07 /pmc/articles/PMC6675726/ /pubmed/31173472 http://dx.doi.org/10.1002/cam4.2107 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Clinical Cancer Research Mora, Barbara Rumi, Elisa Guglielmelli, Paola Barraco, Daniela Maffioli, Margherita Rambaldi, Alessandro Caramella, Marianna Komrokji, Rami Gotlib, Jason Kiladjian, Jean Jacques Cervantes, Francisco Devos, Timothy Palandri, Francesca De Stefano, Valerio Ruggeri, Marco Silver, Richard T. Benevolo, Giulia Albano, Francesco Cavalloni, Chiara Pietra, Daniela Barbui, Tiziano Rotunno, Giada Cazzola, Mario Vannucchi, Alessandro Maria Giorgino, Toni Passamonti, Francesco Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| title | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| title_full | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| title_fullStr | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| title_full_unstemmed | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| title_short | Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients |
| title_sort | second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients |
| topic | Clinical Cancer Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675726/ https://www.ncbi.nlm.nih.gov/pubmed/31173472 http://dx.doi.org/10.1002/cam4.2107 |
| work_keys_str_mv | AT morabarbara secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT rumielisa secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT guglielmellipaola secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT barracodaniela secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT maffiolimargherita secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT rambaldialessandro secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT caramellamarianna secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT komrokjirami secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT gotlibjason secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT kiladjianjeanjacques secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT cervantesfrancisco secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT devostimothy secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT palandrifrancesca secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT destefanovalerio secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT ruggerimarco secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT silverrichardt secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT benevologiulia secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT albanofrancesco secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT cavallonichiara secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT pietradaniela secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT barbuitiziano secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT rotunnogiada secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT cazzolamario secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT vannucchialessandromaria secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT giorginotoni secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients AT passamontifrancesco secondprimarymalignanciesinpostpolycythemiaveraandpostessentialthrombocythemiamyelofibrosisastudyon2233patients |